News

Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine

FREEHOLD, N.J., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, (“Channel” or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, is providing a statement regarding Vertex Pharmaceutical's recently announced Phase 2 data of Suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor in people with painful lumbosacral radiculopathy.

12/20/2024

Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model

FREEHOLD, N.J., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, (“Channel” or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that it achieved its endpoints in two pre-clinical in vivo models of the Company's nerve block formulations for acute pain, showing material improvement over the existing standard of care, bupivacaine, in both efficacy and duration.

12/18/2024

Profitability

Dividends

Income Statement

Balance Sheet

Cash Flow Statement

Symbol Frequently Asked Questions

Is Chromocell Therapeutics Corporation (CHRO) a buy, sell, or hold?

Chromocell Therapeutics Corporation (CHRO) can sell. Click on Rating Page for detail.

What is Chromocell Therapeutics Corporation's stock price?

The price of Chromocell Therapeutics Corporation (CHRO) is 1.9 and it was updated on 2025-01-17 13:00:36.

Is Chromocell Therapeutics Corporation (CHRO) overvalued or undervalued?

Currently Chromocell Therapeutics Corporation (CHRO) is in undervalued.

News

From:

To:

News
Chromocell Announces Name Change to “Channel Therapeutics Corporation” and Provides Therapeutic Program Updates FREEHOLD, N.J., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation, (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that on November 18, 2024 it had changed its name to Channel Therapeutics Corporation (“Channel” or the “Company”), along with reincorporating in the State of Nevada. The Company believes the name change better reflects its focus on developing therapeutics based on sodium channel modulation and blockade for the treatment of pain. Thu, Nov. 21, 2024
Chromocell Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain FREEHOLD, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced the unveiling of its injectable depot program utilizing peripheral nerve blocks for the treatment of post-operative pain. The depot program is based on the Company's novel NaV1.7 molecule for treating chronic pain and eye pain. Tue, Oct. 29, 2024
Chromocell Announces Amendment to Stock Repurchase Plan FREEHOLD, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that its board of directors (the “Board of Directors”) has authorized an amendment (the “Amendment”) to the Company's existing stock repurchase plan (as amended, the “Repurchase Plan”) to increase the total value of shares of Chromocell's common stock (“Common Stock”) available for repurchase by the Company under the Repurchase Plan by an additional $500,000, to $750,000. Thu, Oct. 24, 2024
Chromocell to Participate in Life Sciences Investor Forum September 19th FREEHOLD, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that Frank Knuettel, CEO, will present live at the Life Sciences Investor Forum, hosted by VirtualInvestorConferences.com, on September 19th 2024. Mon, Sep. 16, 2024
Chromocell Announces Stock Repurchase Plan FREEHOLD, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that its board of directors (the “Board of Directors”) has authorized a stock repurchase plan (the “Repurchase Plan”) of up to $250,000 of Chromocell's common stock (“Common Stock”), which represents approximately 23% of the non-affiliate float based on the closing price of the Company's Common Stock as of August 6, 2024. The Repurchase Plan does not obligate the Company to acquire any particular amount of Common Stock, and it may be modified, extended or terminated by the Board of Directors at any time. Wed, Aug. 07, 2024

SEC Filings

SEC Filings
Chromocell Therapeutics Corporation (CHRO) - SCHEDULE 13G SEC Filings 01/15/2025
Chromocell Therapeutics Corporation (CHRO) - EFFECT SEC Filings 12/20/2024
Chromocell Therapeutics Corporation (CHRO) - POS AM SEC Filings 12/11/2024
Chromocell Therapeutics Corporation (CHRO) - EFFECT SEC Filings 12/03/2024
Chromocell Therapeutics Corporation (CHRO) - POS AM SEC Filings 11/22/2024
Chromocell Therapeutics Corporation (CHRO) - 8-K - Current report SEC Filings 11/21/2024
Chromocell Therapeutics Corporation (CHRO) - 8-K12G3 - Current report SEC Filings 11/19/2024
Chromocell Therapeutics Corporation (CHRO) - 8-K - Current report SEC Filings 11/18/2024
Chromocell Therapeutics Corporation (CHRO) - 4 SEC Filings 11/15/2024
Chromocell Therapeutics Corporation (CHRO) - SC 13G/A SEC Filings 11/13/2024
Chromocell Therapeutics Corporation (CHRO) - 424B3 SEC Filings 11/13/2024
Chromocell Therapeutics Corporation (CHRO) - 10-Q - Quarterly Report SEC Filings 11/13/2024
Chromocell Therapeutics Corporation (CHRO) - 8-K - Current report SEC Filings 10/24/2024
Chromocell Therapeutics Corporation (CHRO) - DEF 14A SEC Filings 09/26/2024
Chromocell Therapeutics Corporation (CHRO) - 4 SEC Filings 09/16/2024
Chromocell Therapeutics Corporation (CHRO) - 4 SEC Filings 09/12/2024
Chromocell Therapeutics Corporation (CHRO) - PRE 14A SEC Filings 09/09/2024
Chromocell Therapeutics Corporation (CHRO) - 424B3 SEC Filings 08/13/2024
Chromocell Therapeutics Corporation (CHRO) - 10-Q - Quarterly Report SEC Filings 08/13/2024
Chromocell Therapeutics Corporation (CHRO) - EFFECT SEC Filings 08/07/2024
Chromocell Therapeutics Corporation (CHRO) - 8-K - Current report SEC Filings 08/07/2024
Chromocell Therapeutics Corporation (CHRO) - D SEC Filings 08/06/2024
Chromocell Therapeutics Corporation (CHRO) - 424B3 SEC Filings 08/06/2024
Chromocell Therapeutics Corporation (CHRO) - S-1 SEC Filings 07/29/2024
Chromocell Therapeutics Corporation (CHRO) - 8-K - Current report SEC Filings 07/29/2024
Chromocell Therapeutics Corporation (CHRO) - 424B3 SEC Filings 07/29/2024
Chromocell Therapeutics Corporation (CHRO) - 4 SEC Filings 07/02/2024
Chromocell Therapeutics Corporation (CHRO) - 3/A SEC Filings 07/02/2024
Chromocell Therapeutics Corporation (CHRO) - 4/A SEC Filings 06/18/2024
Chromocell Therapeutics Corporation (CHRO) - 4 SEC Filings 06/18/2024
Chromocell Therapeutics Corporation (CHRO) - 424B3 SEC Filings 05/15/2024
Chromocell Therapeutics Corporation (CHRO) - 10-Q - Quarterly Report SEC Filings 05/15/2024
Chromocell Therapeutics Corporation (CHRO) - POS EX SEC Filings 04/17/2024
Chromocell Therapeutics Corporation (CHRO) - 424B3 SEC Filings 04/17/2024
Chromocell Therapeutics Corporation (CHRO) - 10-K - Current report SEC Filings 04/16/2024
Chromocell Therapeutics Corporation (CHRO) - S-8 SEC Filings 04/15/2024
Chromocell Therapeutics Corporation (CHRO) - 8-K - Current report SEC Filings 04/09/2024
Chromocell Therapeutics Corporation (CHRO) - NT 10-K - Current report SEC Filings 04/01/2024
Chromocell Therapeutics Corporation (CHRO) - 8-K - Current report SEC Filings 03/21/2024
Chromocell Therapeutics Corporation (CHRO) - 8-K - Current report SEC Filings 03/18/2024
Chromocell Therapeutics Corporation (CHRO) - 8-K - Current report SEC Filings 03/13/2024
Chromocell Therapeutics Corporation (CHRO) - 4/A SEC Filings 03/12/2024
Chromocell Therapeutics Corporation (CHRO) - SC 13G SEC Filings 03/04/2024
Chromocell Therapeutics Corporation (CHRO) - SC 13G SEC Filings 03/01/2024
Chromocell Therapeutics Corporation (CHRO) - SC 13D SEC Filings 02/26/2024
Chromocell Therapeutics Corporation (CHRO) - 4 SEC Filings 02/23/2024
Chromocell Therapeutics Corporation (CHRO) - 8-K - Current report SEC Filings 02/22/2024
Chromocell Therapeutics Corporation (CHRO) - SEC STAFF LETTER SEC Filings 02/20/2024
Chromocell Therapeutics Corporation (CHRO) - 424B4 SEC Filings 02/20/2024
Chromocell Therapeutics Corporation (CHRO) - POS EX SEC Filings 02/16/2024
Chromocell Therapeutics Corporation (CHRO) - EFFECT SEC Filings 02/15/2024
Chromocell Therapeutics Corporation (CHRO) - CERT SEC Filings 02/15/2024
Chromocell Therapeutics Corporation (CHRO) - 8-A12B SEC Filings 02/15/2024
Chromocell Therapeutics Corporation (CHRO) - 3 SEC Filings 02/15/2024
Chromocell Therapeutics Corporation (CHRO) - S-1/A SEC Filings 02/14/2024
Chromocell Therapeutics Corporation (CHRO) - S-1/A SEC Filings 02/12/2024
Chromocell Therapeutics Corporation (CHRO) - FWP SEC Filings 02/12/2024
Chromocell Therapeutics Corporation (CHRO) - CORRESP SEC Filings 02/12/2024
Chromocell Therapeutics Corporation (CHRO) - S-1/A SEC Filings 02/07/2024
Chromocell Therapeutics Corporation (CHRO) - FWP SEC Filings 02/07/2024
Chromocell Therapeutics Corporation (CHRO) - FWP SEC Filings 01/31/2024
Chromocell Therapeutics Corporation (CHRO) - S-1/A SEC Filings 01/30/2024
Chromocell Therapeutics Corporation (CHRO) - CORRESP SEC Filings 01/30/2024
Chromocell Therapeutics Corporation (CHRO) - UPLOAD SEC Filings 01/25/2024
Chromocell Therapeutics Corporation (CHRO) - SEC STAFF LETTER SEC Filings 01/23/2024
Chromocell Therapeutics Corporation (CHRO) - S-1/A SEC Filings 01/16/2024
Chromocell Therapeutics Corporation (CHRO) - S-1/A SEC Filings 11/08/2023
Chromocell Therapeutics Corporation (CHRO) - FWP SEC Filings 11/08/2023
Chromocell Therapeutics Corporation (CHRO) - S-1/A SEC Filings 10/25/2023
Chromocell Therapeutics Corporation (CHRO) - UPLOAD SEC Filings 10/24/2023
Chromocell Therapeutics Corporation (CHRO) - S-1/A SEC Filings 10/16/2023
Chromocell Therapeutics Corporation (CHRO) - FWP SEC Filings 10/16/2023
Chromocell Therapeutics Corporation (CHRO) - CORRESP SEC Filings 10/13/2023
Chromocell Therapeutics Corporation (CHRO) - UPLOAD SEC Filings 09/12/2023
Chromocell Therapeutics Corporation (CHRO) - S-1/A SEC Filings 09/01/2023
Chromocell Therapeutics Corporation (CHRO) - CORRESP SEC Filings 09/01/2023
Chromocell Therapeutics Corporation (CHRO) - CORRESP SEC Filings 07/24/2023
Chromocell Therapeutics Corporation (CHRO) - S-1/A SEC Filings 07/20/2023
Chromocell Therapeutics Corporation (CHRO) - UPLOAD SEC Filings 07/10/2023
Chromocell Therapeutics Corporation (CHRO) - S-1/A SEC Filings 06/30/2023
Chromocell Therapeutics Corporation (CHRO) - CORRESP SEC Filings 06/30/2023
Chromocell Therapeutics Corporation (CHRO) - UPLOAD SEC Filings 05/19/2023
Chromocell Therapeutics Corporation (CHRO) - S-1/A SEC Filings 05/01/2023
Chromocell Therapeutics Corporation (CHRO) - CORRESP SEC Filings 05/01/2023
Chromocell Therapeutics Corporation (CHRO) - UPLOAD SEC Filings 01/23/2023
Chromocell Therapeutics Corporation (CHRO) - S-1/A SEC Filings 01/20/2023
Chromocell Therapeutics Corporation (CHRO) - S-1 SEC Filings 01/11/2023
Chromocell Therapeutics Corporation (CHRO) - CORRESP SEC Filings 01/11/2023
Chromocell Therapeutics Corporation (CHRO) - UPLOAD SEC Filings 10/31/2022
Chromocell Therapeutics Corporation (CHRO) - DRS/A SEC Filings 10/17/2022
Chromocell Therapeutics Corporation (CHRO) - DRSLTR SEC Filings 10/14/2022
Chromocell Therapeutics Corporation (CHRO) - UPLOAD SEC Filings 10/03/2022
Chromocell Therapeutics Corporation (CHRO) - DRS SEC Filings 09/06/2022
Chromocell Therapeutics Corporation (CHRO) - 8-K - Current report SEC Filings 11/04/2019
Chromocell Therapeutics Corporation (CHRO) - 8-K - Current report SEC Filings 08/30/2019
Chromocell Therapeutics Corporation (CHRO) - 8-K - Current report SEC Filings 08/01/2019
Chromocell Therapeutics Corporation (CHRO) - 10-Q - Quarterly Report SEC Filings 05/20/2019
Chromocell Therapeutics Corporation (CHRO) - NT 10-Q - Quarterly Report SEC Filings 05/15/2019
Chromocell Therapeutics Corporation (CHRO) - 10-K - Current report SEC Filings 04/15/2019
Chromocell Therapeutics Corporation (CHRO) - 8-K - Current report SEC Filings 04/05/2019
Chromocell Therapeutics Corporation (CHRO) - NT 10-K - Current report SEC Filings 03/29/2019
Chromocell Therapeutics Corporation (CHRO) - 8-K/A - Current report SEC Filings 01/03/2019
Chromocell Therapeutics Corporation (CHRO) - 8-K - Current report SEC Filings 01/03/2019
Chromocell Therapeutics Corporation (CHRO) - 8-K - Current report SEC Filings 12/14/2018
Chromocell Therapeutics Corporation (CHRO) - NT 10-Q - Quarterly Report SEC Filings 11/15/2018
Chromocell Therapeutics Corporation (CHRO) - 10-Q - Quarterly Report SEC Filings 11/15/2018
Chromocell Therapeutics Corporation (CHRO) - UPLOAD SEC Filings 08/20/2018
Chromocell Therapeutics Corporation (CHRO) - DEF 14C SEC Filings 08/20/2018
Chromocell Therapeutics Corporation (CHRO) - PRER14C SEC Filings 08/16/2018
Chromocell Therapeutics Corporation (CHRO) - UPLOAD SEC Filings 08/15/2018
Chromocell Therapeutics Corporation (CHRO) - 10-Q - Quarterly Report SEC Filings 08/14/2018
Chromocell Therapeutics Corporation (CHRO) - PRE 14C SEC Filings 08/02/2018
Chromocell Therapeutics Corporation (CHRO) - 8-K - Current report SEC Filings 07/20/2018
Chromocell Therapeutics Corporation (CHRO) - 8-K - Current report SEC Filings 07/10/2018
Chromocell Therapeutics Corporation (CHRO) - 8-K - Current report SEC Filings 06/18/2018
Chromocell Therapeutics Corporation (CHRO) - 10-Q - Quarterly Report SEC Filings 05/21/2018
Chromocell Therapeutics Corporation (CHRO) - NT 10-Q - Quarterly Report SEC Filings 05/15/2018
Chromocell Therapeutics Corporation (CHRO) - DEF 14C SEC Filings 05/14/2018
Chromocell Therapeutics Corporation (CHRO) - 8-K - Current report SEC Filings 04/09/2018
Chromocell Therapeutics Corporation (CHRO) - 10-K - Current report SEC Filings 04/09/2018
Chromocell Therapeutics Corporation (CHRO) - NT 10-K - Current report SEC Filings 04/02/2018
Chromocell Therapeutics Corporation (CHRO) - 8-K - Current report SEC Filings 03/15/2018
Chromocell Therapeutics Corporation (CHRO) - 8-K - Current report SEC Filings 01/26/2018
Chromocell Therapeutics Corporation (CHRO) - DEF 14C SEC Filings 12/29/2017
Chromocell Therapeutics Corporation (CHRO) - 8-K - Current report SEC Filings 12/20/2017
Chromocell Therapeutics Corporation (CHRO) - PRE 14C SEC Filings 12/18/2017
Chromocell Therapeutics Corporation (CHRO) - 424B3 SEC Filings 12/08/2017
Chromocell Therapeutics Corporation (CHRO) - EFFECT SEC Filings 12/07/2017
Chromocell Therapeutics Corporation (CHRO) - S-1/A SEC Filings 12/06/2017
Chromocell Therapeutics Corporation (CHRO) - CORRESP SEC Filings 12/06/2017
Chromocell Therapeutics Corporation (CHRO) - CORRESP SEC Filings 12/05/2017
Chromocell Therapeutics Corporation (CHRO) - 8-K - Current report SEC Filings 11/30/2017
Chromocell Therapeutics Corporation (CHRO) - 8-K - Current report SEC Filings 11/21/2017
Chromocell Therapeutics Corporation (CHRO) - UPLOAD SEC Filings 11/15/2017
Chromocell Therapeutics Corporation (CHRO) - 10-Q - Quarterly Report SEC Filings 11/14/2017
Chromocell Therapeutics Corporation (CHRO) - S-1 SEC Filings 11/08/2017
Chromocell Therapeutics Corporation (CHRO) - 8-K - Current report SEC Filings 11/08/2017
Chromocell Therapeutics Corporation (CHRO) - 8-K - Current report SEC Filings 11/06/2017
Chromocell Therapeutics Corporation (CHRO) - DEF 14C SEC Filings 11/02/2017
Chromocell Therapeutics Corporation (CHRO) - PRE 14C SEC Filings 10/20/2017
Chromocell Therapeutics Corporation (CHRO) - 10-Q - Quarterly Report SEC Filings 08/21/2017
Chromocell Therapeutics Corporation (CHRO) - NT 10-Q - Quarterly Report SEC Filings 08/15/2017
Chromocell Therapeutics Corporation (CHRO) - 8-K - Current report SEC Filings 08/09/2017
Chromocell Therapeutics Corporation (CHRO) - UPLOAD SEC Filings 07/17/2017
Chromocell Therapeutics Corporation (CHRO) - 10-12G/A SEC Filings 07/10/2017
Chromocell Therapeutics Corporation (CHRO) - CORRESP SEC Filings 07/07/2017
Chromocell Therapeutics Corporation (CHRO) - CORRESP SEC Filings 06/20/2017
Chromocell Therapeutics Corporation (CHRO) - 10-12G/A SEC Filings 06/20/2017
Chromocell Therapeutics Corporation (CHRO) - CORRESP SEC Filings 06/16/2017
Chromocell Therapeutics Corporation (CHRO) - 10-12G/A SEC Filings 06/16/2017
Chromocell Therapeutics Corporation (CHRO) - UPLOAD SEC Filings 06/12/2017
Chromocell Therapeutics Corporation (CHRO) - CORRESP SEC Filings 05/26/2017
Chromocell Therapeutics Corporation (CHRO) - 10-12G/A SEC Filings 05/26/2017
Chromocell Therapeutics Corporation (CHRO) - UPLOAD SEC Filings 05/18/2017
Chromocell Therapeutics Corporation (CHRO) - 10-12G SEC Filings 04/21/2017
Chromocell Therapeutics Corporation (CHRO) - D SEC Filings 11/25/2013
Chromocell Therapeutics Corporation (CHRO) - D SEC Filings 11/21/2013
Chromocell Therapeutics Corporation (CHRO) - REGDEX/A SEC Filings 01/30/2008
Chromocell Therapeutics Corporation (CHRO) - REGDEX SEC Filings 12/19/2006

Press Releases

StockPrice Release
Channel therapeutics highlights differences between nav1.7 and nav1.8 in light of recent clinical data on suzetrigine 12/20/2024
Channel therapeutics announces positive efficacy data for a depot formulation of a nav1.7 inhibitor in a preclinical in vivo nerve block model 12/18/2024
Chromocell announces name change to “channel therapeutics corporation” and provides therapeutic program updates 11/21/2024
Chromocell announces unveiling of injectable depot program for the treatment of surgical pain 10/29/2024
Chromocell announces amendment to stock repurchase plan 10/24/2024
Chromocell to participate in life sciences investor forum september 19th 09/16/2024
Chromocell announces stock repurchase plan 08/07/2024
Chromocell to participate in the virtual investor lunch break series 07/15/2024
Paycom announces promotions of randy peck to coo, jennifer kraszewski to chro and matt paque to clo 05/31/2024
Prologis' nekritz and mckeown to retire; new clo and chro announced 05/22/2024
Chromocell to present at alliance global partner's healthcare company showcase on tuesday, may 21, 2024 05/13/2024
Chromocell issues letter to stockholders from chief executive officer 04/09/2024
Chromocell announces formal launch of eye pain treatment program and hiring of dr. simon chandler 03/21/2024
Chromocell names frank knuettel as chief executive officer, removing interim status held since july 2023 03/18/2024
Chromocell to present at sidoti virtual investor conference march 13-14 03/11/2024
Benuvia operations, llc and chromocell therapeutics corp. announce strategic partnership to advance healthcare solutions 02/27/2024
Chromocell therapeutics announces closing of initial public offering for gross proceeds of $6.6 million 02/21/2024
Chromocell therapeutics announces pricing of upsized $6.6 initial public offering 02/16/2024

More Headlines

News
Chromocell to Participate in the Virtual Investor Lunch Break Series Live webcast with Frank Knuettel II, Chief Executive Officer and Chief Financial Officer, on Thursday, July 18th at 12:00 PM ET Live webcast with Frank Knuettel II, Chief Executive Officer and Chief Financial Officer, on Thursday, July 18th at 12:00 PM ET 07/15/2024
Paycom Announces Promotions of Randy Peck to COO, Jennifer Kraszewski to CHRO and Matt Paque to CLO OKLAHOMA CITY--(BUSINESS WIRE)--Paycom Software, Inc. (NYSE: PAYC) (“Paycom” or the “Company”), a leading provider of comprehensive, cloud-based human capital management software, announced that Randy Peck, a 20-year Paycom veteran, has been appointed to serve as Paycom's Chief Operating Officer, while Matt Paque and Jennifer Kraszewski have been promoted to Chief Legal Officer and Chief Human Resources Officer, respectively. “These promotions align with our ambition to continue to help Paycom. 05/31/2024
PROLOGIS' NEKRITZ AND MCKEOWN TO RETIRE; NEW CLO AND CHRO ANNOUNCED Briones and Carey to join company's executive committee on Jan. 1, 2025 SAN FRANCISCO , May 22, 2024 /PRNewswire/ -- Prologis (NYSE: PLD) today announced Ed Nekritz and Colleen McKeown will retire as chief legal officer and chief human resources officer, effective January 1, 2025. Current Deputy General Counsel Deborah Briones and Senior Vice President of Human Resources Nathaalie Carey will succeed Nekritz and McKeown. 05/22/2024
Chromocell To Present at Alliance Global Partner's Healthcare Company Showcase on Tuesday, May 21, 2024 FREEHOLD, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that its CEO Frank Knuettel, will be presenting at Alliance Global Partners Healthcare Company Showcase on Tuesday, May 21, 2024. 05/13/2024
Chromocell Issues Letter to Stockholders from Chief Executive Officer FREEHOLD, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that its Chief Executive Officer, Frank Knuettel, has issued the following letter to stockholders: 04/09/2024
Chromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler FREEHOLD, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that it has formally launched its eye pain treatment program with the hiring of Dr. Simon Chandler. 03/21/2024
Chromocell Names Frank Knuettel as Chief Executive Officer, Removing Interim Status Held Since July 2023 FREEHOLD, N.J., March 18, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that its interim CEO Frank Knuettel, has been appointed as the Company's permanent CEO. 03/18/2024
Chromocell to Present at Sidoti Virtual Investor Conference March 13-14 AUSTIN, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced Frank Knuettel, CEO, will present and host one-on-one meetings with investors at the Sidoti March Virtual Investor Conference, taking place on March 13-14, 2024. 03/11/2024
Benuvia Operations, LLC and Chromocell Therapeutics Corp. Announce Strategic Partnership to Advance Healthcare Solutions AUSTIN. Texas, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Benuvia Operations, LLC (“Benuvia”), a leader in pharmaceutical innovation, and Chromocell Therapeutics Corp. (“Chromocell”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, are pleased to announce Chromocell's first Development and License Agreement (“Agreement”). Under the Agreement, Chromocell licensed sublingual formulation of a Diclofenac spray for the treatment of acute pain, a Rizatriptan intranasal spray formulation and an Ondansetron sublingual spray formulation, diversifying our pipeline of non-opioid pain treatment therapies, while adding therapeutic options for related conditions. This collaboration leverages the unique strengths of both organizations to enhance patient outcomes and address unmet medical needs. 02/27/2024
Chromocell Therapeutics Announces Closing of Initial Public Offering for Gross Proceeds of $6.6 Million FREEHOLD, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (NYSE American: CHRO) (“Chromocell”, “our”, “us” or the “Company”), a clinical-stage biotech company focused on developing and commercializing new, non-opioid therapeutics to alleviate pain, today announced the closing of its initial public offering of 1,100,000 shares of its common stock at a public offering price of $6.00 per share. The gross proceeds from the offering to Chromocell, before deducting the underwriting discounts and estimated offering expenses, were approximately $6.6 million. Chromocell's common stock is listed on the NYSE American LLC under the ticker symbol “CHRO”. 02/21/2024
U.S. IPO Weekly Recap: Nano-Caps Debut In Quiet Week U.S. IPO Weekly Recap: Nano-Caps Debut In Quiet Week 02/17/2024
Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering FREEHOLD, N.J., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (NYSE American: CHRO) (“Chromocell” or the “Company”), a clinical-stage biotech company focused on developing and commercializing new, non-opioid therapeutics to alleviate pain, today announced the pricing of its initial public offering of 1,100,000 shares of common stock at a public offering price of $6.00 per share. The offering raised aggregate gross proceeds of approximately $6.6 million, prior to deducting underwriting discounts and other offering expenses. 02/16/2024
IPO Update: Chromocell Therapeutics Seeks $8.7 Million In Micro-IPO Chromocell Therapeutics Corporation has filed for an $8.7 million IPO to develop its treatment for chronic pain conditions. The company's lead compound is being prepared for a Phase 2a study for erythromelalgia patients with a genetic component. 10/19/2023

Unlock

CHRO Ratings Summary

CHRO Quant Ranking